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Aims: Chronic thromboembolic pulmonary hypertension (CTEPH) is a devastating disease, and treating patients
with CTEPHwho are not eligible for pulmonary endarterectomy is particularly challenging. Short-term bosentan
or phosphodiesterase type-5-inhibitor treatment can greatly improve symptoms and hemodynamics in these
patients; however, the long-termbeneﬁts of advanced pulmonary vasodilators are not known.We retrospectively
investigated the long-term effects of advanced pharmacological therapy in Japanese patients with inoperable
CTEPH.
Main methods: Seven consecutive patients with inoperable CTEPH (ﬁve women; mean age, 62.6 ± 6.9 years)
treated with bosentan were included. World Health Organization functional class (WHO-FC), hemodynamics,
exercise capacity, and plasma B-type natriuretic peptide (BNP) concentration were evaluated at baseline and
for more than 2 years. Time to clinical worsening was also examined during long-term follow-up.
Key ﬁndings:WHO-FC improved signiﬁcantly, from 3.1 ± 0.4 to 2.1 ± 0.4 (p= 0.005). Signiﬁcant improvement
was also seen in pulmonary vascular resistance, which decreased from 786.9 ± 300.0 to 352.2 ± 210.7 dynes
s cm−5 (p b 0.05). Plasma BNP concentration decreased signiﬁcantly from 1160.0 ± 971.4 to 305.1 ±
285.9 pg/mL (p b 0.05). No patient required hospitalization during the follow-up period (mean, 896±564 days).
Signiﬁcance: Long-term advanced therapy with bosentan signiﬁcantly improves symptoms, pulmonary vascular
resistance, plasma BNP concentration, and time to clinical worsening in Japanese patients with inoperable
CTEPH. We consider bosentan to be an essential treatment for these patients.
© 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is a
devastating disease. It has been reported that the 5-year survival rate
in Japanese patients with CTEPH is almost 60%, and that median survival
is only 6.8 years (Nakanishi et al., 1997; Kunieda et al., 1999). A mean
pulmonary artery pressure (mPAP) greater than 30 mm Hg indicates a
much worse prognosis than one less than 30 mm Hg (Nakanishi et al.,
1997; Lewczuk et al., 2001). The only approved drug treatment for
CTEPH is warfarin, which can improve the prognosis of these patients,
while pulmonary endarterectomy (PEA) provides a potential cure and
much better prognosis for patients with centrally damaged pulmonary
arteries (Dartevelle et al., 2004). The treatment of patients who are notedicine, Department of Internal
3311-1 Yakushiji, Shimotsuke,
1 285 44 5317.
icle under the CC BY-NC-ND license (eligible for PEA because of the involvement of distal pulmonary arteries
remains challenging.
In CTEPH the pathological lesions are organized thrombi tightly
attached to the medial layer of elastic pulmonary arteries, replacing the
normal intima. These may completely occlude the lumen or form areas
of stenosis, webs, or bands. Interestingly, histological changes in the
non-occluded pulmonary arteries are similar to those seen in pulmonary
artery hypertension (PAH), such as medial hypertrophy and the intimal
proliferative and ﬁbrotic changes that include plexiform lesions (Galiè
and Kim, 2006).
As the pathological changes in the pulmonary vasculature appear
similar, new pulmonary vasodilating drugs used to treat PAH have also
been used in CTEPH: prostanoids (Ono et al., 2003; Cabrol et al., 2007;
Skoro-Sajer et al., 2007), endothelin-receptor antagonists (ERAs)
(Becattini et al., 2010), and phosphodiesterase type-5 (PDE5) inhibitors
(Suntharalingam et al., 2008) are reported to have hemodynamic and
clinical beneﬁts, although these have not been established in random-
ized, placebo-controlled trials. Nonetheless, the prognosis of Japanese
patients with CTEPH is improving: it has recently been reported thathttp://creativecommons.org/licenses/by-nc-nd/ .0/).3
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speciﬁc therapies by almost two-thirds of patients (Nishimura et al.,
2013). Currently 37.9% of patients in a CTEPH international registry are
recorded as receiving at least one PAH-targeted therapy (Pepke-Zaba
et al., 2011).
Recently riociguat, a novel soluble guanylate cyclase stimulator
licensed for the treatment of PAH, has been shown to signiﬁcantly
improve exercise capacity and pulmonary vascular resistance (PVR) in
patients with inoperable CTEPH or persistent CTEPH after PEA over a
16-week period (Ghofrani et al., 2013). Riociguat appears to have the
potential to become the gold standard therapy for CTEPH, although its
long-term effects are not known and it is not yet available in Japan.
Of the other PAH-speciﬁc drugs, only bosentan caneffect a signiﬁcant
reduction in PVR and plasma N-terminal fragment (NT-pro) B-type na-
triuretic peptide (BNP) concentrations, and a signiﬁcant improvement
in cardiac index (CI) (Jaïs et al., 2008). Importantly, however, BENEFiT
(Bosentan Effects in iNopErable Forms of chronIc Thromboembolic
pulmonary hypertension), a 16-week randomized, placebo-controlled
clinical trial undertaken in patients with inoperable CTEPH or persistent
CTEPH after PEA, reported no improvement in functional outcomes such
as 6-minute walk distance (6MWD), World Health Organization func-
tional class (WHO-FC), or time to clinical worsening. Bosentan may
offer a therapeutic option for Japanese patients with inoperable CTEPH
or persistent CTEPH after PEA, but again its long-term beneﬁts are not
known. We retrospectively investigated the effects of bosentan on the
symptoms, hemodynamics, exercise capacity, plasma BNP concentra-
tions and time to clinical worsening when it was used as part of a treat-
ment strategy for pulmonary hypertension (PH) in Japanese patients
with inoperable CTEPH over a 2-year period.Table 1
Baseline clinical, functional, and hemodynamic characteristics.
Variable
Age, yrs 62.6 ± 6.9
Male Female, n 2 5
Previous PEA, n 0
WHO-FC, II/III/IV, n 0/6/1
mPAP, mmHg (n = 3) 47.0 ± 7.6
PVR, dsc−5 (n = 3) 786.9 ± 300.0
CI, L/min/m2 (n = 3) 2.18 ± 0.39
6MWD, m (n = 4) 257.0 ± 151.0
BNP, pg/mL 1160.0 ± 971.4
Medications
Warfarin 2–6 mg, n 7
Beraprost 120 μg, n 5
Sildenaﬁl 60 mg, n 4
Hypertension 1
Diabetes mellitus 4
Hyperlipidemia 2
Renal failure 2
Hyperuricemia 5
Data are presented as mean ± standard deviation unless otherwise
indicated.
Abbreviations: BNP, plasma B-type natriuretic peptide; CI, cardiac index;
WHO-FC, World Health Organization functional class; mPAP, mean pulmo-
nary artery pressure; 6MWD, 6-minute walk distance; PEA, pulmonary
endarterectomy; PVR, pulmonary vascular resistance.Patients and methods
The records of consecutive Japanese patients treated with bosentan
for symptomatic, inoperable CTEPH at Jichi Medical University Hospital
between May 2007 and April 2012 were analyzed retrospectively.
All patients met the requirements for CTEPH as follows: pre-capillary
PH reﬂected by a mean pulmonary artery pressure (mPAP)
≥25 mm Hg, pulmonary capillary wedge pressure ≤15 mm Hg and
PVR N2 Wood units in patients with multiple chronic (N6 months) or
organized occlusive thrombi or emboli in the elastic pulmonary arteries
(Galiè et al., 2009) (Supplemental Table 2). Hemodynamic parameters
weremeasured by right heart catheterization andpulmonary artery dis-
ease was detected by ventilation-perfusion lung scan and multirow
computed tomography (CT). In ﬁve patients, pulmonary artery (PA)
clots were successfully treated with warfarin for N1 year before
bosentan was initiated. In one patient, no PA thrombus could be detect-
ed after a 4-month course of warfarin, and blood D-dimer concentra-
tions were below the limit of detection. In the ﬁnal patient, no PA
thrombus was seen on CT angiography and the levels of D-dimer were
in the normal range before warfarin was administered (Supplemental
Table 6). All patients were considered to be inoperable because of pe-
ripheral PA stenosis. The WHO-FC, hemodynamic parameters, exercise
capacity, and plasma BNP concentrations were evaluated at baseline
and routinely during follow-up. Right heart catheterization was repeat-
ed just before or after initiation of bosentan (supplemental Table 4); on
each occasion it was performed 6 to 8 h after the patient had taken their
normal dose of bosentan, beraprost and/or sildenaﬁl. Time to clinical
worsening due to PH, deﬁned as hospitalization, lung transplantation
or death, was also recorded. No speciﬁc treatment algorithm was used.
Advanced therapies such as prostanoids or PDE5 inhibitors were com-
menced at the discretion of the supervising physician.
All data are presented as mean ± standard deviation. A paired
t-test was used to compare variables at baseline and during follow-
up after initiation of bosentan. A p value of b0.05 was considered
signiﬁcant.Results
Seven consecutive patients with symptomatic inoperable CTEPH
were enrolled (two men, ﬁve women; mean age 62.6 ± 6.9 years).
None had previously undergone PEA or balloon pulmonary angioplasty
(BPA). Six were WHO-FC III and one was WHO-FC IV before the initia-
tion of bosentan. Patient background information, including symptoms,
laboratory values, and treatment regimens are presented in Table 1.
Before the initiation of bosentan, all patients had been treated with war-
farin, ﬁve had been treated with beraprost and four with sildenaﬁl. Six
patients were treated with diuretics (Supplemental Table 3). Co-
morbidities included diabetes mellitus in four patients, impaired
glucose tolerance in one patient, hypercholesterolemia in two
patients, renal dysfunction in two patients and hyperuricemia in
ﬁve patients (Supplemental Table 1).
After bosentan was added to supplement standard PAH-speciﬁc
therapy, WHO-FC signiﬁcantly improved from IV to III in one patient
and from III to II in 6 patients (p = 0.005). In three patients in whom
right heart catheterization was performed just before or after initiation
of bosentan (cases 4, 5 and 6 at 1 year, 9 months and 1 year 9 months
after initiation of bosentan, respectively; Supplemental Table 4), mean
PVR signiﬁcantly decreased from 786.9 ± 300.0 dynes s cm−5 to
352.2 ± 210.7 dynes s cm−5 (p b 0.05) over 22 months. Mean plasma
BNP concentration also decreased signiﬁcantly, from 1160.0 ±
971.4 pg/mL to 305.1 ± 285.9 pg/mL (p b 0.05). We also observed
several results that suggested a trend toward improvement, but did not
reach statistical signiﬁcance: 6MWD increased from 257.0 ± 151.0 m to
360.8 ± 80.4 m (p= 0.11, n=4, follow-up 708± 120 days), mPAP de-
creased from 47.0 ± 7.6 mmHg to 41.3 ± 8.3 mm Hg and CI increased
from 2.18 ± 0.39 L/min/m2 to 3.59 ± 1.72 L/min/m2 (n= 3, follow-up
671 ± 116 days; Fig. 1A–F). No patient's condition worsened and none
required hospitalization during the follow-up period; notably one patient
had required inpatient hospital treatment 11 times before bosentan was
started (median follow-up period, ~28 months). The details of drugs
used in the follow-up period are shown in the supplemental Tables 4
and 5.
Discussion
Our results show that advanced therapy with bosentan over 2 years
improvesWHO-FC, PVR, plasma BNP concentrations, and time to clinical
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Fig. 1. Change in parameters of disease severity pre- and post-combination therapy with
bosentan in Japanese patients with CTEPH: (A)WHO-FC, (B) 6MWD; (C)mPAP, (D) PVR,
(E) CI, (F) plasma BNP. Values shown as mean ± standard deviation. Abbreviations: BNP,
plasmaB-typenatriuretic peptide; CI, cardiac index; FC, functional class;mPAP,meanpulmo-
nary artery pressure; 6MWD, 6-minute walk distance; PVR, pulmonary vascular resistance;
WHO-FC, World Health Organization functional class.
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dition worsened and no patient required hospitalization during the
follow-up period of over 2 years; a therapeutic effect that is illustrated
by a representative patient who never deteriorated after initiation of
bosentan, although prior to its initiation had required hospitalization
on 11 occasions for worsening right heart failure.
A national cohort study of patientswith CTEPH has been performed in
theUnited Kingdom (Condliffe et al., 2008). Although therewas no differ-
ence inpulmonaryhemodynamics or exercise tolerance betweenpatients
diagnosed from 2001 to 2002 and those diagnosed after 2003, the prog-
nosis of patients with inoperable CTEPH diagnosed after 2003 improved
signiﬁcantly compared with that of the earlier group, to 1- and 3-year
survival rates of 83% and 76%, respectively. After 2003, the proportion of
patients treated with PAH-speciﬁc therapy increased from 70% to 90%;
in particular, the proportion of patients treated with ERAs increased
from17% to 56% andwith PDE5 inhibitors, from 0% to 33%, at the expense
of the proportion treated with prostanoids, which declined from 83% to
11% (Condliffe et al., 2008). This report supports our ﬁnding that
advanced PAH-speciﬁc drugs such as bosentan can improve long-term
outcomes in patients with inoperable CTEPH.In this study, apparent improvements in 6MWD, mPAP, and CI after
advanced therapy with bosentan did not meet signiﬁcance because of
the small number of patients enrolled. We were able to investigate
hemodynamic changes in only three patients. Of the remaining four
patients, hemodynamic analysis by right heart catheterization was not
performed immediately before initiation of bosentan in three and was
not performed after initiation of bosentan in one (and the follow-up
period was only 217 days).
Our study has several limitations, the most important being the
small sample size—although it should be noted that inoperable CTEPH
is rare and these numbers are typical even of a large tertiary referral
center. The open-label design may also have inﬂuenced the extent of
improvement in functional outcome measures, even though these did
not reach statistical signiﬁcance. The strengths of our study are that it
reﬂects the real-life use of bosentan in specialist clinical practice, and
that follow-up was maintained for more than 2 years, when most
clinical trials have been conducted over 4 months. Even so, the efﬁcacy
of advanced therapy with bosentan over a period longer than 3 years is
still unknown. To show reliable evidence of advanced PAH-speciﬁc
therapy on inoperable CTEPH or persistent CTEPH after PEA, further
investigation is needed with larger prospective studies that are
randomized, double-blinded, and conducted over longer periods.
Riociguat improves exercise capacity and hemodynamics in patients
with inoperable CTEPH or persistent CTEPH after PEA in the short term
(Ghofrani et al., 2013). Combined therapywith riociguat and other PAH-
speciﬁc drugsmay further improve the prognosis of patients with inop-
erable CTEPH. In addition, BPA has recently been reﬁned for use in
patients with inoperable CTEPH (Mizoguchi et al., 2012). Although
BPA was ﬁrst reported over a decade ago, its clinical application has
been restricted because of limited efﬁcacy and potentially serious com-
plications (Voorburg et al., 1988; Feinstein et al., 2001). The reﬁned
technique is, however, reported to reduce periprocedural mortality
and improve functional status and hemodynamics very substantially,
including an improvement in mPAP from 45 mm Hg to nearly normal.
In the near future, a combination of advanced PAH-speciﬁc therapy
and BPA may become standard therapy for patients with inoperable
CTEPH or persistent CTEPH after PEA.
Conclusions
Our ﬁndings provide new insight into the treatment of inoperable
CTEPH. Combination therapy with bosentan improves WHO-FC, PVR,
BNP concentrations, and time to clinical worsening in Japanese patients
with inoperable CTEPH over 2 years. Advanced therapy with bosentan
appears to be an effective means of improving the prognosis of patients
with inoperable CTEPH.
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